The Administration Core serves to direct and support the research and development programs ofthe GNL. A dedicated leadership team ensures the safe and secure operations ofthe laboratory, oversees programs and assesses the quality of work done, provides financial and business services, facilitates community relafions and communications, ensures full compliance with select agent rules and regulations, provides information services, coordinates external program reviews and independent peer evaluations, and communicates with both UTMB administration and the NIH, NIAID Biodefense and Emerging Infecfious Diseases program management. By providing a consolidated administrative support structure, the Core efficiently utilizes resources, avoids duplication of efforts by subordinate organizational elements, and serves as a single point of contact for accurate and consistent informafion dissemination.

Public Health Relevance

The Administration Core directs the research and development programs ofthe GNL, oversees the quality of work and ensures the safe and secure operations of the laboratory as well as compliance with select agent regulations. The consolidated administrative support structure efficiently utilizes resources, avoids duplication, and serves as a single point of contact for accurate and consistent information dissemination.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI094660-02
Application #
8376435
Study Section
Special Emphasis Panel (ZAI1-PRJ-M)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
2
Fiscal Year
2012
Total Cost
$1,042,142
Indirect Cost
$321,248
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:
Mire, Chad E; Cross, Robert W; Geisbert, Joan B et al. (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:1146-1149
Thi, Emily P; Mire, Chad E; Lee, Amy Ch et al. (2017) siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J Clin Invest :
Satterfield, Benjamin A; Cross, Robert W; Fenton, Karla A et al. (2016) Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets. J Virol 90:6326-43
Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430
Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah et al. (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12:2351-6
Thi, Emily P; Lee, Amy C H; Geisbert, Joan B et al. (2016) Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol 1:16142
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus. J Infect Dis 214:S263-S267
Cross, Robert W; Mire, Chad E; Branco, Luis M et al. (2016) Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res 133:218-222
Olsen, Michelle E; Filone, Claire Marie; Rozelle, Dan et al. (2016) Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication. MBio 7:

Showing the most recent 10 out of 54 publications